Literature DB >> 16344070

erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer.

Guan-Hua Lai1, Zichen Zhang, Xue-Ning Shen, Deanna J Ward, Jennifer L Dewitt, Shawn E Holt, Rebecca A Rozich, Douglas C Hixson, Alphonse E Sirica.   

Abstract

BACKGROUND & AIMS: Cholangiocarcinomas appear to arise from the malignant transformation of cholangiocytes lining the biliary tract. Because the development of an in vitro model of malignant transformation can provide a powerful new tool for establishing critical events governing the molecular pathogenesis of cholangiocarcinoma, we investigated the potential of achieving malignant transformation of cultured rat cholangiocytes in relation to aberrant overexpression of mutationally activated erbB-2/neu.
METHODS: Malignant neoplastic transformation was achieved after infection of the rat cholangiocyte cell line, designated BDE1, with the retrovirus Glu664-neu, containing the transforming rat erbB-2/neu oncogene.
RESULTS: Compared with untransformed control cells, malignant transformants carrying the activating erbB-2/neu mutation prominently overexpressed p185neu receptor protein, which was phosphorylated strongly at its major autophosphorylation site at tyrosine 1248. Moreover, erbB-2/neu transformation of BDE1 cells resulted in increased telomerase activity, up-regulation of cyclooxygenase-2 with overproduction of prostaglandin E(2), enhanced phosphorylation of mitogen-activated protein kinase and of serine/threonine kinase Akt/PKB, overexpression of vascular endothelial growth factor, and increased mucin 1 messenger RNA expression. Only erbB-2/neu transformants were tumorigenic when transplanted into isogeneic rats, yielding a 100% incidence of tumors closely resembling human desmoplastic ductal cholangiocarcinomas in their morphology. Malignant cholangiocytes in the tumors were strongly immunoreactive for biliary cytokeratin 19, p185neu, and cyclooxygenase-2.
CONCLUSIONS: This unique malignant transformation model recapitulates key molecular features of the human disease and appears to be well suited for testing novel molecular therapeutic strategies against cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344070     DOI: 10.1053/j.gastro.2005.10.010

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

2.  Targeting PDGFR-β in Cholangiocarcinoma.

Authors:  Christian D Fingas; Joachim C Mertens; Nataliya Razumilava; Steven F Bronk; Alphonse E Sirica; Gregory J Gores
Journal:  Liver Int       Date:  2011-12-02       Impact factor: 5.828

Review 3.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

4.  Soft agar-based selection of spontaneously transformed rat prostate epithelial cells with highly tumorigenic characteristics.

Authors:  Martina Šrajer Gajdošik; Douglas C Hixson; Kate E Brilliant; DongQin Yang; Monique E De Paepe; Djuro Josić; David R Mills
Journal:  Exp Mol Pathol       Date:  2018-05-29       Impact factor: 3.362

5.  Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.

Authors:  Miguel Á Manzanares; Akihiro Usui; Deanna J Campbell; Catherine I Dumur; Gabrielle T Maldonado; Michel Fausther; Jonathan A Dranoff; Alphonse E Sirica
Journal:  Am J Pathol       Date:  2017-03-15       Impact factor: 4.307

6.  Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

Authors:  Michael R O'Dell; Jing Li Huang; Christa L Whitney-Miller; Vikram Deshpande; Paul Rothberg; Valerie Grose; Randall M Rossi; Andrew X Zhu; Hartmut Land; Nabeel Bardeesy; Aram F Hezel
Journal:  Cancer Res       Date:  2012-01-20       Impact factor: 12.701

7.  A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells.

Authors:  Christian D Fingas; Boris R A Blechacz; Rory L Smoot; Maria E Guicciardi; Justin Mott; Steve F Bronk; Nathan W Werneburg; Alphonse E Sirica; Gregory J Gores
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

8.  Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma.

Authors:  Nataliya Razumilava; Sergio A Gradilone; Rory L Smoot; Joachim C Mertens; Steven F Bronk; Alphonse E Sirica; Gregory J Gores
Journal:  J Hepatol       Date:  2013-11-14       Impact factor: 25.083

9.  HDAC6 inhibition restores ciliary expression and decreases tumor growth.

Authors:  Sergio A Gradilone; Brynn N Radtke; Pamela S Bogert; Bing Q Huang; Gabriella B Gajdos; Nicholas F LaRusso
Journal:  Cancer Res       Date:  2013-01-31       Impact factor: 12.701

10.  Leptin enhances cholangiocarcinoma cell growth.

Authors:  Giammarco Fava; Gianfranco Alpini; Chiara Rychlicki; Stefania Saccomanno; Sharon DeMorrow; Luciano Trozzi; Cinzia Candelaresi; Julie Venter; Antonio Di Sario; Marco Marzioni; Italo Bearzi; Shannon Glaser; Domenico Alvaro; Luca Marucci; Heather Francis; Gianluca Svegliati-Baroni; Antonio Benedetti
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.